医学研究与教育 ›› 2022, Vol. 39 ›› Issue (6): 24-28.DOI: 10.3969/j.issn.1674-490X.2022.06.004

• 临床医学 • 上一篇    下一篇

雷珠单抗联合复方血栓通胶囊和视网膜光凝治疗视网膜分支静脉阻塞合并黄斑水肿

张虎,郝建章,齐峰,冯玮,王青   

  1. 保定市第一医院眼科, 河北 保定 071000
  • 收稿日期:2022-11-17 出版日期:2022-12-25 发布日期:2022-12-25
  • 作者简介:张虎(1974—),男,河北保定人,主任医师,硕士,主要从事眼底疾病的研究。 E-mail: zhanghu696@163.com
  • 基金资助:
    保定市科学技术研究与发展计划项目(2041ZF054)

  • Received:2022-11-17 Online:2022-12-25 Published:2022-12-25

摘要: 目的 对比口服复方血栓通胶囊联合视网膜光凝与玻璃体腔注射雷珠单抗联合视网膜光凝和口服复方血栓通胶囊治疗视网膜分支静脉阻塞合并黄斑水肿的治疗效果。方法 回顾性分析确诊为视网膜分支静脉阻塞合并黄斑水肿的42例患者42眼,按不同治疗方案分为2组:试验组(21眼)为玻璃体腔注射雷珠单抗联合复方口服血栓通胶囊和视网膜光凝治疗组,对照组(21眼)为复方血栓通联合视网膜激光光凝治疗组。试验组先行雷珠单抗玻璃体腔注射,同时口服复方血栓通胶囊,3个月后行视网膜激光光凝;对照组行视网膜光凝和口服复方血栓通胶囊。观察治疗6个月2组患者的最佳矫正视力,黄斑中心凹视网膜厚度变化。结果 治疗6个月后2组最佳矫正视力均提高,试验组优于对照组;眼科光学相干断层扫描显示试验组黄斑中心凹厚度平均降低415.51 μm(61.45%),对照组黄斑中心凹厚度平均降低120.51 μm(27.40%),试验组优于对照组。结论 玻璃体腔注射雷珠单抗联合口服复方血栓通胶囊和视网膜光凝治疗视网膜分支静脉阻塞合并黄斑水肿安全有效。

关键词: 雷珠单抗, 复方血栓通胶囊, 视网膜光凝, 视网膜分支静脉阻塞, 黄斑水肿

Abstract: Objective To compare the therapeutic effect of oral compound thrombolysis capsules combined with retinal photocoagulation, intravitreal injection ranibizumab and oral compound thrombolysis capsules combined with retinal photocoagulation in the treatment of retinal branch vein occlusion and macular edema. Methods A retrospective analysis was conducted in 42 patients with 42 eyes diagnosed with retinal branch vein occlusion and macular edema, and the patients were divided into two groups according to different treatment regimens: the experimental group(21 eyes)was treated with intravitreal injection ranibizumab combined with compound oral thrombolysis capsules and retinal photocoagulation, the control group(21 eyes)was given the compound thrombolysis capsule combined with retinal laser photocoagulation, the experimental group received ranibizumab intravitreal injection, while oral thrombolysis capsule, and retinal laser photocoagulation was performed 3 months later. The two groups underwent simple retinal photocoagulation and oral thrombosis capsules. The optimal corrected visual acuity of the two groups was examined during the 6-month treatment period, the changes of macular foveal retinal thickness were determined.Results After 6 months of treatment, the optimal corrected visual acuity of both groups was improved, and the treating effects of the experimental group was better than that of the control group, and the ophthalmic optical coherence tomography showed that the macular foveal thickness was reduced by 415.51 μm(61.45%)in the combination treatment group and 120.51 μm(27.40%)in the control group, which indicated that the treating effects of the experimental group was better than that of the controls. Conclusion Intravitreal injection of ranibizumab combined with oral compound thrombolysis capsule and retinal photocoagulation is safe and effective in the treatment of retinal branch vein occlusion and macular edema.

Key words: ranibizumab injections, compound thrombolysis capsule, retinal photocoagulation, retinal vein embolism, macular edema

中图分类号: